

Je-Hwan Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5774540/publications.pdf>

Version: 2024-02-01

187
papers

3,814
citations

172207

29
h-index

155451

55
g-index

191
all docs

191
docs citations

191
times ranked

5080
citing authors

#	ARTICLE	IF	CITATIONS
1	Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML. <i>New England Journal of Medicine</i> , 2019, 381, 1728-1740.	13.9	796
2	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	0.6	160
3	A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. <i>Blood</i> , 2011, 118, 3832-3841.	0.6	136
4	Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 696-704.	2.0	118
5	Randomized Trial of Myeloablative Conditioning Regimens: Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine. <i>Journal of Clinical Oncology</i> , 2013, 31, 701-709.	0.8	99
6	Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. <i>International Journal of Hematology</i> , 2013, 97, 749-757.	0.7	98
7	Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. <i>Blood</i> , 2011, 118, 2609-2617.	0.6	94
8	Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. <i>Annals of Hematology</i> , 2005, 84, 321-330.	0.8	84
9	Acute myeloid leukemia patients clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts. <i>Haematologica</i> , 2016, 101, e185-e188.	1.7	68
10	Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. <i>Cancer</i> , 1995, 75, 2794-2801.	2.0	65
11	Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2017, 35, 2754-2763.	0.8	65
12	Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. <i>Lancet Haematology</i> , 2015, 2, e417-e426.	2.2	64
13	Randomized Comparison of Four-Times-Daily versus Once-Daily Intravenous Busulfan in Conditioning Therapy for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1095-1105.	2.0	62
14	Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2016, 7, 55264-55275.	0.8	62
15	A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. <i>Haematologica</i> , 2011, 96, 1441-1447.	1.7	58
16	Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. <i>British Journal of Haematology</i> , 2002, 118, 1087-1094.	1.2	56
17	Influence of GST Gene Polymorphisms on the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1222-1230.	2.0	55
18	Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. <i>Journal of Korean Medical Science</i> , 2016, 31, 214.	1.1	51

#	ARTICLE	IF	CITATIONS
19	Changes of isoagglutinin titres after ABO-incompatible allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2003, 120, 702-710.	1.2	48
20	Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia. <i>Haematologica</i> , 2005, 90, 1380-8.	1.7	45
21	Prognostic implications of the immunophenotype in biphenotypic acute leukemia. <i>Leukemia and Lymphoma</i> , 2008, 49, 700-709.	0.6	44
22	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. <i>Blood</i> , 2018, 132, 2736-2736.	0.6	44
23	Significance of fibrinogen, D-dimer, and LDH levels in predicting the risk of bleeding in patients with acute promyelocytic leukemia. <i>Leukemia Research</i> , 2011, 35, 152-158.	0.4	40
24	A prospective longitudinal study evaluating the usefulness of the interferon-gamma releasing assay for predicting active tuberculosis in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2014, 69, 165-173.	1.7	38
25	Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 2032-2043.	2.5	38
26	Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2015, 90, 1013-1020.	2.0	37
27	Incidence, characteristics, and treatment outcomes of mycobacterial diseases in transplant recipients. <i>Transplant International</i> , 2016, 29, 549-558.	0.8	34
28	Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 510-518.	1.7	33
29	C3435T polymorphism of the MDR1 gene is not associated with P-glycoprotein function of leukemic blasts and clinical outcome in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 1601-1604.	0.4	32
30	Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. <i>Leukemia Research</i> , 2011, 35, 499-503.	0.4	31
31	Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen-Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2065-2076.	2.0	31
32	Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation. <i>Leukemia Research</i> , 2001, 25, 305-312.	0.4	29
33	Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of the RISK-Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1773-1779.	2.0	29
34	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study. <i>Leukemia Research</i> , 2021, 100, 106489.	0.4	29
35	High Dose Dexamethasone Vs. Conventional Dose Prednisolone for Adults with Immune Thrombocytopenia: a Prospective Multicenter Phase III Trial. <i>Blood</i> , 2010, 116, 3687-3687.	0.6	29
36	Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome. <i>Annals of Hematology</i> , 2013, 92, 889-897.	0.8	27

#	ARTICLE	IF	CITATIONS
37	Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing. PLoS ONE, 2016, 11, e0167641.	1.1	27
38	Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms. Blood Research, 2013, 48, 178.	0.5	26
39	A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Annals of Hematology, 2012, 91, 1459-1469.	0.8	25
40	Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells. PLoS ONE, 2015, 10, e0119379.	1.1	24
41	Feasible Outcomes of T Cell Replete Haploidentical Stem Cell Transplantation with Reduced-Intensity Conditioning in Patients with Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2015, 21, 342-349.	2.0	23
42	Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. Haematologica, 2005, 90, 285-6.	1.7	23
43	Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal, 2022, 12, .	2.8	23
44	Alterations in the bone marrow microenvironment may elicit defective hematopoiesis: a comparison of aplastic anemia, chronic myeloid leukemia, and normal bone marrow. Experimental Hematology, 2017, 45, 56-63.	0.2	22
45	Comparison of anthracyclines used for induction chemotherapy in patients with FLT3 -ITD-mutated acute myeloid leukemia. Leukemia Research, 2018, 68, 51-56.	0.4	22
46	Phase 1 study of CWP232291 in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).. Journal of Clinical Oncology, 2015, 33, 7044-7044.	0.8	22
47	Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2003, 122, 637-644.	1.2	21
48	Prognostic role of FEV ₁ for survival in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation, 2015, 29, 1133-1139.	0.8	21
49	Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biology of Blood and Marrow Transplantation, 2017, 23, 1555-1566.	2.0	21
50	Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Korean Journal of Physiology and Pharmacology, 2016, 20, 63.	0.6	20
51	Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD). Bone Marrow Transplantation, 2019, 54, 1361-1368.	1.3	20
52	Clinical Implications of Non-A-Type NPM1 and FLT3 Mutations in Patients with Normal Karyotype Acute Myeloid Leukemia. Acta Haematologica, 2012, 127, 63-71.	0.7	19
53	Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy. Korean Journal of Internal Medicine, 2016, 31, 961-970.	0.7	19
54	Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. Blood, 2021, 138, 700-700.	0.6	18

#	ARTICLE	IF	CITATIONS
55	Single nucleotide polymorphism of Wilmsâ€™ tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. <i>Annals of Hematology</i> , 2012, 91, 671-677.	0.8	17
56	A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome. <i>Oncotarget</i> , 2015, 6, 44985-44994.	0.8	17
57	Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes. <i>International Journal of Hematology</i> , 2014, 99, 635-643.	0.7	16
58	<i>JAK2</i> V617F, <i>MPL</i> , and <i>CALR</i> Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis. <i>Journal of Korean Medical Science</i> , 2015, 30, 882.	1.1	16
59	Fludarabine, cytarabine, and attenuated-dose idarubicin (â€œFLAI) combination therapy for elderly acute myeloid leukemia patients. <i>American Journal of Hematology</i> , 2013, 88, 10-15.	2.0	14
60	Cytogenetic profiles of 2806 patients with acute myeloid leukemiaâ€”a retrospective multicenter nationwide study. <i>Annals of Hematology</i> , 2016, 95, 1223-1232.	0.8	14
61	Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. <i>Annals of Hematology</i> , 2016, 95, 125-133.	0.8	14
62	Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5. <i>Oncotarget</i> , 2017, 8, 11748-11762.	0.8	14
63	Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 390-400.	0.7	14
64	Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia. <i>Leukemia Research</i> , 2006, 30, 204-210.	0.4	13
65	Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. <i>Blood Research</i> , 2013, 48, 87.	0.5	13
66	A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. <i>Journal of Korean Medical Science</i> , 2021, 36, e306.	1.1	13
67	Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia. <i>Leukemia Research</i> , 2001, 25, 213-216.	0.4	12
68	Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression. <i>Blood Research</i> , 2015, 50, 227.	0.5	12
69	Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2015, 134, 40-48.	0.7	12
70	Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome. <i>European Journal of Haematology</i> , 2015, 94, 546-553.	1.1	11
71	A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60Ây with resistant acute myeloid leukemia: a comparison with intensive younger patientsâ€™ trial. <i>European Journal of Haematology</i> , 2016, 96, 188-197.	1.1	11
72	Efficacy of eculizumab in paroxysmal nocturnal hemoglobinuria patients with or without aplastic anemia: prospective study of a Korean PNH cohort. <i>Blood Research</i> , 2017, 52, 207.	0.5	11

#	ARTICLE	IF	CITATIONS
73	Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics. <i>Leukemia Research</i> , 2009, 33, 426-433.	0.4	10
74	Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. <i>Annals of Hematology</i> , 2010, 89, 15-23.	0.8	10
75	Clinical effect of reduced-intensity conditioning regimen containing antithymocyte globulin for hematopoietic cell transplantation from unrelated donors. <i>American Journal of Hematology</i> , 2011, 86, 399-405.	2.0	10
76	Diagnostic usefulness of dynamic changes of CMV-specific T-cell responses in predicting CMV infections in HCT recipients. <i>Journal of Clinical Virology</i> , 2017, 87, 5-11.	1.6	10
77	Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2223-2232.	2.0	10
78	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. <i>HemaSphere</i> , 2021, 5, e617.	1.2	10
79	Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia. <i>European Journal of Haematology</i> , 2011, 87, 172-181.	1.1	9
80	A t(8;9)(p22;p24)/PCM1-JAK2 Translocation in a Patient With Myeloproliferative Neoplasm and Myeloid Sarcoma: First Report in Korea. <i>Annals of Laboratory Medicine</i> , 2016, 36, 79-81.	1.2	9
81	Comparable Allogeneic Hematopoietic Cell Transplantation Outcome of a Haplo-Identical Family Donor with an Alternative Donor in Adult Aplastic Anemia. <i>Acta Haematologica</i> , 2016, 136, 129-139.	0.7	9
82	TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome. <i>Leukemia Research</i> , 2018, 74, 97-104.	0.4	9
83	Different prognostic effects of core-binding factor positive AML with Korean AML registry data. <i>Annals of Hematology</i> , 2019, 98, 1135-1147.	0.8	9
84	Treatment of Latent Tuberculosis Infection Based on the Interferon- γ Release Assay in Allogeneic Stem Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2020, 71, 1977-1979.	2.9	9
85	Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells. <i>Oncotarget</i> , 2017, 8, 41387-41400.	0.8	9
86	Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. <i>Leukemia Research</i> , 2017, 60, 135-144.	0.4	8
87	Clinical characteristics and outcomes of patients with chronic disseminated candidiasis who need adjuvant corticosteroid therapy. <i>Medical Mycology</i> , 2018, 56, 782-786.	0.3	8
88	Fludarabine/Melphalan 100 mg/m ² Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1116-1121.	2.0	8
89	Prognostic implications of CD14 positivity in acute myeloid leukemia arising from myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2013, 97, 246-255.	0.7	7
90	Uncontrolled Complement Activation and the Resulting Chronic Hemolysis As Measured by LDH Serum Level At Diagnosis As Predictor of Thrombotic Complications and Mortality in a Large Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2011, 118, 3166-3166.	0.6	7

#	ARTICLE	IF	CITATIONS
91	Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study. <i>Blood</i> , 2015, 126, 2861-2861.	0.6	7
92	Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2006, 85, 357-365.	0.8	6
93	Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 290-299.e3.	0.2	6
94	Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial. <i>International Journal of Hematology</i> , 2021, 113, 851-860.	0.7	6
95	Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study. <i>Blood</i> , 2011, 118, 1517-1517.	0.6	6
96	Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2022, 198, 703-712.	1.2	6
97	Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia. <i>Leukemia Research</i> , 2009, 33, 511-517.	0.4	5
98	Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2013, 92, 1101-1110.	0.8	5
99	Recurrent pulmonary embolism during dabigatran treatment in a patient with immune thrombocytopenic purpura. <i>Thrombosis Research</i> , 2016, 148, 23-24.	0.8	5
100	Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. <i>Annals of Hematology</i> , 2017, 96, 605-615.	0.8	5
101	Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study. <i>British Journal of Haematology</i> , 2019, 187, e4-e7.	1.2	5
102	Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 656-664.	0.2	5
103	Incidence, Management, and Prognosis of Graft Failure and Autologous Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2021, 36, e151.	1.1	5
104	Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. <i>European Journal of Haematology</i> , 2022, 109, 58-68.	1.1	5
105	A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy. <i>Annals of Hematology</i> , 2011, 90, 1283-1291.	0.8	4
106	Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea. <i>Journal of Korean Medical Science</i> , 2014, 29, 61.	1.1	4
107	Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation. <i>Blood Research</i> , 2015, 50, 123.	0.5	4
108	Monosomal karyotype in acute myeloid leukemia and the role of allogeneic hematopoietic cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 795-801.	0.8	4

#	ARTICLE	IF	CITATIONS
109	A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 655-663.	0.2	4
110	Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5%—a feasibility study. <i>Annals of Hematology</i> , 2016, 95, 1151-1161.	0.8	4
111	Restrictive chronic lung function decline after haematopoietic stem cell transplantation. <i>European Respiratory Journal</i> , 2016, 47, 336-339.	3.1	4
112	Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. <i>Blood Research</i> , 2018, 53, 288.	0.5	4
113	The Detailed Kinetics of Cytomegalovirus-specific T cell Responses after Hematopoietic Stem Cell Transplantation: 1 Year Follow-up Data. <i>Immune Network</i> , 2018, 18, e2.	1.6	4
114	Blast Percentage of Bone Marrow Aspirate on Day 14 of Induction Chemotherapy Predicts Adult Acute Lymphoblastic Leukemia Treatment Outcomes. <i>Acta Haematologica</i> , 2018, 139, 220-227.	0.7	4
115	Use of Droplet Digital Polymerase Chain Reaction for Detecting Minimal Residual Disease: A Prospective Multi-Institutional Study. <i>In Vivo</i> , 2019, 33, 2273-2280.	0.6	4
116	Second allogeneic hematopoietic stem cell transplantation in patients with acute leukemia relapsed after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14199.	0.8	4
117	Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis. <i>Medicine (United States)</i> , 2021, 100, e25448.	0.4	4
118	Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry. <i>PLoS ONE</i> , 2021, 16, e0251011.	1.1	4
119	Extracorporeal Membrane Oxygenation Support in Adult Patients with Hematologic Malignancies and Severe Acute Respiratory Failure. <i>Korean Journal of Critical Care Medicine</i> , 2016, 31, 243-250.	0.1	4
120	Up-Front Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Arising from the Myelodysplastic Syndrome. <i>Acta Haematologica</i> , 2015, 133, 183-192.	0.7	3
121	Monosomal karyotype affecting outcomes of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission. <i>European Journal of Haematology</i> , 2020, 105, 262-273.	1.1	3
122	DDX41 mutation in Patients with Idiopathic Cytopenia of Undetermined Significance, Myelodysplastic Syndrome, and Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3002-3002.	0.6	3
123	Clinical impact of anti-thymocyte globulin on survival and graft-versus-host disease in patients undergoing human leukocyte antigen mismatched allogeneic stem cell transplantation. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 429-437.	0.7	3
124	Predicting Long-term Survival After Allogeneic Hematopoietic Cell Transplantation in Patients With Hematologic Malignancies: Machine Learning-Based Model Development and Validation. <i>JMIR Medical Informatics</i> , 2022, 10, e32313.	1.3	3
125	Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission. <i>The Korean Journal of Hematology</i> , 2010, 45, 95.	0.7	2
126	Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome. <i>British Journal of Haematology</i> , 2019, 186, e151-e155.	1.2	2

#	ARTICLE	IF	CITATIONS
127	Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma. <i>Annals of Laboratory Medicine</i> , 2019, 39, 496-498.	1.2	2
128	Diagnostic usefulness of differential time to positivity in neutropenic cancer patients with suspected catheter-related candidemia. <i>Medical Mycology</i> , 2020, 58, 137-140.	0.3	2
129	Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). <i>Bone Marrow Transplantation</i> , 2020, 55, 1466-1468.	1.3	2
130	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. <i>Annals of Hematology</i> , 2021, 100, 189-196.	0.8	2
131	Diagnostic yield of a bronchoalveolar lavage fluid galactomannan assay in patients with negative serum galactomannan results suspected to have invasive pulmonary aspergillosis. <i>Mycoses</i> , 2021, 64, 1124-1131.	1.8	2
132	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	1.0	2
133	Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 179-189.	0.7	2
134	Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation. <i>Korean Journal of Physiology and Pharmacology</i> , 2016, 20, 245.	0.6	1
135	Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 159-166.	0.7	1
136	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2310.	1.0	1
137	Clinical implications of copy number alteration detection using panel-based next-generation sequencing data in myelodysplastic syndrome. <i>Leukemia Research</i> , 2021, 103, 106540.	0.4	1
138	Granulocytic and Monocytic Myeloid-Derived Suppressor Cells are Functionally and Prognostically Different in Patients with Chronic Myeloid Leukemia. <i>Annals of Laboratory Medicine</i> , 2021, 41, 479-484.	1.2	1
139	Hypoplastic Acute Myeloid Leukemia.. <i>Blood</i> , 2006, 108, 4493-4493.	0.6	1
140	Autologous Versus Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Peripheral T-Cell Lymphomas (PTCLs): Japan and Korea Cooperative Study with 330 Patients.. <i>Blood</i> , 2009, 114, 2284-2284.	0.6	1
141	A Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in the Induction Chemotherapy for Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2535-2535.	0.6	1
142	Two Cycles of PAD Combination (PS-341/Bortezomib, Adriamycin and Dexamethasone) Followed by Autologous Hematopoietic Cell Transplantation (AHCT) in Newly Diagnosed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2009, 114, 2322-2322.	0.6	1
143	Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation. <i>Blood</i> . 2010. 116. 3536-3536.	0.6	1
144	Prognostic Implications of CD14 Positivity in Acute Myeloid Leukemia Arising From Myleodysplastic Syndrome., <i>Blood</i> , 2011, 118, 3523-3523.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Clinical Signs and Symptoms In Non-Transfused Patients With Paroxysmal Nocturnal Hemoglobinuria From a Korean Prospective PNH Registry. <i>Blood</i> , 2013, 122, 3720-3720.	0.6	1
146	Retrospective Case Series Study of Hypomethylating Therapy in IPSS Lower-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1992-1992.	0.6	1
147	Allogeneic hematopoietic cell transplantation for lymphoma: baseline and posttransplant prognostic factors. <i>Leukemia and Lymphoma</i> , 2018, 59, 1829-1839.	0.6	0
148	Immunodeficiency risk score for prediction of mortality by parainfluenza virus infection in patients with hematologic malignancy. <i>Annals of Hematology</i> , 2020, 99, 1231-1239.	0.8	0
149	Clinical features and outcomes of hypocellular acute myeloid leukemia in adults. <i>Medicine (United States)</i> , 2021, 100, 1000000.	0.4	0
150	Lenalidomide for anemia correction in lower-risk del(5q) myelodysplastic syndrome patients of Asian ethnicity. <i>Blood Research</i> , 2021, 56, 102-108.	0.5	0
151	Prognostic Factors Identifiable at the Time of Onset of Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2004, 104, 1247-1247.	0.6	0
152	A Risk Model for Early Intracranial Hemorrhage in Acute Leukemia. <i>Blood</i> , 2004, 104, 4473-4473.	0.6	0
153	Allogeneic Hematopoietic Cell Transplantation (HCT) for Acute Leukemia in First Relapse or Second Remission. <i>Blood</i> , 2005, 106, 5415-5415.	0.6	0
154	Risk Factor Analysis for Predicting Chronic Graft-Versus-Host Disease of Progressive or Quiescent Type in a Cohort of Patients with a History of Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2005, 106, 5337-5337.	0.6	0
155	Time to First Acute Exacerbation Can Stratify the Patients According to Their Prognosis during Clinical Course of Chronic GVHD: Evaluation of New End-Point for Chronic GVHD. <i>Blood</i> , 2005, 106, 5335-5335.	0.6	0
156	Standard Induction Followed by Attenuated Consolidation Therapy in Elderly Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2005, 106, 4602-4602.	0.6	0
157	Prognostic Implications of the Immunophenotype in Biphenotypic Acute Leukemia. <i>Blood</i> , 2006, 108, 2319-2319.	0.6	0
158	Prognostic Significance of FLT3 Mutations in Paired Initial and Relapse Marrow Samples of Acute Myeloid Leukemia Excluding Acute Promyelocytic Leukemia. <i>Blood</i> , 2006, 108, 4440-4440.	0.6	0
159	Similar Background of Graft-Versus-Host Disease (GVHD) Following Allogeneic Blood and Marrow Transplantation (Tx) in Korean and Japanese Populations Allows a Uniform Foundation To Perform Large-Scale Clinical Studies in the Region. <i>Blood</i> , 2007, 110, 5007-5007.	0.6	0
160	Preliminary Results of a Prospective Multicenter Phase III Trial Comparing High-Dose and Standard-Dose Daunorubicin for Induction of Complete Remission (CR) in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2007, 110, 1833-1833.	0.6	0
161	Prevalence and Trend of Hematopoietic Stem Cell Transplantation for Adult Aplastic Anemia/Pure Red Cell Aplasia in Korea. <i>Blood</i> , 2007, 110, 3757-3757.	0.6	0
162	Continuous Infusion of FLAG and Idarubicin for Patients Younger Than 60 Years with Resistant Acute Myeloid Leukemia; a Prospective, Multicenter Phase II Study. <i>Blood</i> , 2007, 110, 4350-4350.	0.6	0

#	ARTICLE	IF	CITATIONS
163	The Equal Activity of Azacytidine in 4 Risk Groups of IPSS in MDS.. Blood, 2007, 110, 4615-4615.	0.6	0
164	HLA-Haploidentical Familial Donor Hematopoietic Cell Transplantation without Ex Vivo- T Cell Depletion after Reduced-Intensity Conditioning of Busulfan, Fludarabine, and Anti-Thymocyte Globulin: A Preliminary Report.. Blood, 2007, 110, 3077-3077.	0.6	0
165	The Molecular Screening Using Multiplex Reverse Transcription Polymerase Chain Reaction and the Comparison with Cytogenetic Analysis in the Prognostic Stratification of Acute Leukemia. Blood, 2008, 112, 4868-4868.	0.6	0
166	A Case Report of Rituximab Therapy for Recurrent Thrombotic Thrombocytopenia Purpura. The Korean Journal of Hematology, 2009, 44, 193.	0.7	0
167	Influence of Glutathione S-Transferase (GST) Gene Polymorphisms On the Clearance of Intravenous Busulfan in Adult Patients Undergoing Hematopoietic Cell Transplantation.. Blood, 2009, 114, 1179-1179.	0.6	0
168	Multicenter Retrospective Analysis of Second Allogeneic HSCT Outcomes for Hematologic Malignancies in Korea.. Blood, 2009, 114, 4298-4298.	0.6	0
169	Genomic Copy Number Alterations and Clustering Analysis Using Array CGH in Acute Myeloid Leukemia with Normal Karyotype.. Blood, 2009, 114, 1008-1008.	0.6	0
170	Rapid Detection of Nucleophosmin (NPM1) Mutations to Determine Prognostic Implications in Acute Myeloid Leukemia Patients with a Normal Karyotype.. Blood, 2009, 114, 4676-4676.	0.6	0
171	Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia: Role of the NPM1 Mutations May Be Different in Different Races.. Blood, 2009, 114, 4684-4684.	0.6	0
172	Hematopoietic Cell Transplantation from an HLA-Mismatched Familial Donor After Reduced-Intensity Conditioning Containing Busulfan, Fludarabine, and Antithymocyte Globulin for Patients with Acute Leukemia and Myelodysplastic Syndrome. Blood, 2010, 116, 3538-3538.	0.6	0
173	Prospective Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition to Anti-Thymocyte Globulin for the Conditioning Therapy In Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome. Blood, 2010, 116, 34-34.	0.6	0
174	Immediate Allogeneic Hematopoietic Cell Transplantation (HCT) in Acute Myeloid Leukemia (AML) Arising From Myelodysplastic Syndrome (MDS). Blood, 2011, 118, 2031-2031.	0.6	0
175	Retrospective Comparison of Azacitidine and Decitabine in the Treatment of Myleodysplastic Syndrome., Blood, 2011, 118, 3809-3809.	0.6	0
176	Validation of New Prognostic Model Including Comorbidities in Patients with Myleodysplastic Syndrome Receiving Hypomethylating Therapy. Blood, 2011, 118, 1708-1708.	0.6	0
177	Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2011, 118, 5273-5273.	0.6	0
178	Efficacy Of Helicobacter Pylori Eradication For The First Line Treatment Of Immune Thrombocytopenia Patients With Moderate Thrombocytopenia. Blood, 2013, 122, 2324-2324.	0.6	0
179	Comparable Allogeneic Hematopoietic Cell Transplantation Outcome Of Haplo-Identical Family Donor With Matched Unrelated/Mismatched Family Donor In Adult Aplastic Anemia. Blood, 2013, 122, 1230-1230.	0.6	0
180	Azacitidine-Induced Lung Injury in a Patient with Myelodysplastic Syndrome. Korean Journal of Medicine, 2014, 87, 496.	0.1	0

#	ARTICLE	IF	CITATIONS
181	Ineffective Corticosteroid Treatment for Hemolysis Management of Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2014, 124, 5151-5151.	0.6	0
182	Long-Term Follow-up of Continuous Imatinib Plus Combination Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3654-3654.	0.6	0
183	A Prospective Randomized Comparison of Cyclophosphamide Versus Fludarabine in Addition of Antithymocyte Globuline for Allogeneic Hematopoietic Cell Transplantation in Patients with Adult Severe Aplastic Anemia; Interim Analysis. <i>Blood</i> , 2014, 124, 3890-3890.	0.6	0
184	Comparable Outcomes with Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients with or without Aplastic Anemia in a Prospective Korean PNH Registry. <i>Blood</i> , 2015, 126, 4789-4789.	0.6	0
185	Mutational Characteristics and Changing Pattern from Idiopathic Cytopenia of Undetermined Significance to High-Risk Myelodysplastic Syndrome Stratified By IPSS-R. <i>Blood</i> , 2019, 134, 3009-3009.	0.6	0
186	A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3425-3425.	0.6	0
187	Similar Survival and Genetic Features between Clonal Cytopenia of Undetermined Significance and Lower-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2021, 138, 3683-3683.	0.6	0